Charles A. Gersbach, Ph.D. - Publications

Biomedical Engineering Duke University, Durham, NC 

65 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Black JB, Adler AF, Wang HG, D'Ippolito AM, Hutchinson HA, Reddy TE, Pitt GS, Leong KW, Gersbach CA. Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells. Cell Stem Cell. PMID 27524438 DOI: 10.1016/j.stem.2016.07.001  0.56
2016 Moutos FT, Glass KA, Compton SA, Ross AK, Gersbach CA, Guilak F, Estes BT. Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing. Proceedings of the National Academy of Sciences of the United States of America. PMID 27432980 DOI: 10.1073/pnas.1601639113  0.56
2016 Nelson CE, Gersbach CA. Engineering Delivery Vehicles for Genome Editing. Annual Review of Chemical and Biomolecular Engineering. PMID 27146557 DOI: 10.1146/annurev-chembioeng-080615-034711  0.56
2016 Nelson CE, Gersbach CA. Cas9 loosens its grip on off-target sites. Nature Biotechnology. 34: 298-9. PMID 26963555 DOI: 10.1038/nbt.3501  0.56
2016 Thakore PI, Gersbach CA. Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors. Methods in Molecular Biology (Clifton, N.J.). 1338: 71-88. PMID 26443215 DOI: 10.1007/978-1-4939-2932-0_7  0.56
2016 Ousterout DG, Gersbach CA. The Development of TALE Nucleases for Biotechnology. Methods in Molecular Biology (Clifton, N.J.). 1338: 27-42. PMID 26443211 DOI: 10.1007/978-1-4939-2932-0_3  0.56
2015 Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX, Asokan A, Zhang F, Duan D, Gersbach CA. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science (New York, N.Y.). PMID 26721684 DOI: 10.1126/science.aad5143  0.56
2015 Thakore PI, D'Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Reddy TE, Crawford GE, Gersbach CA. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nature Methods. PMID 26501517 DOI: 10.1038/nmeth.3630  0.56
2015 Hilton IB, Gersbach CA. Enabling functional genomics with genome engineering. Genome Research. 25: 1442-55. PMID 26430154 DOI: 10.1101/gr.190124.115  0.56
2015 Polstein LR, Perez-Pinera P, Kocak DD, Vockley CM, Bledsoe P, Song L, Safi A, Crawford GE, Reddy TE, Gersbach CA. Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators. Genome Research. PMID 26025803 DOI: 10.1101/gr.179044.114  0.56
2015 Gibson TM, Gersbach CA. Single-molecule analysis of myocyte differentiation reveals bimodal lineage commitment. Integrative Biology : Quantitative Biosciences From Nano to Macro. 7: 663-71. PMID 25953198 DOI: 10.1039/c5ib00057b  0.56
2015 Frank CL, Liu F, Wijayatunge R, Song L, Biegler MT, Yang MG, Vockley CM, Safi A, Gersbach CA, Crawford GE, West AE. Regulation of chromatin accessibility and Zic binding at enhancers in the developing cerebellum. Nature Neuroscience. 18: 647-56. PMID 25849986 DOI: 10.1038/nn.3995  0.56
2015 Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nature Biotechnology. 33: 510-7. PMID 25849900 DOI: 10.1038/nbt.3199  0.56
2015 Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nature Communications. 6: 6244. PMID 25692716 DOI: 10.1038/ncomms7244  0.56
2015 Polstein LR, Gersbach CA. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nature Chemical Biology. 11: 198-200. PMID 25664691 DOI: 10.1038/nchembio.1753  0.56
2015 Diekman BO, Thakore PI, O'Connor SK, Willard VP, Brunger JM, Christoforou N, Leong KW, Gersbach CA, Guilak F. Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells. Tissue Engineering. Part A. 21: 1261-74. PMID 25517798 DOI: 10.1089/ten.TEA.2014.0240  0.56
2015 Kabadi AM, Thakore PI, Vockley CM, Ousterout DG, Gibson TM, Guilak F, Reddy TE, Gersbach CA. Enhanced MyoD-Induced Transdifferentiation to a Myogenic Lineage by Fusion to a Potent Transactivation Domain. Acs Synthetic Biology. 4: 689-99. PMID 25494287 DOI: 10.1021/sb500322u  0.56
2015 Ousterout DG, Kabadi AM, Thakore PI, Perez-Pinera P, Brown MT, Majoros WH, Reddy TE, Gersbach CA. Correction of dystrophin expression in cells from duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 523-32. PMID 25492562 DOI: 10.1038/mt.2014.234  0.56
2014 Chakraborty S, Ji H, Chen J, Gersbach CA, Leong KW. Vector modifications to eliminate transposase expression following piggyBac-mediated transgenesis. Scientific Reports. 4: 7403. PMID 25492703 DOI: 10.1038/srep07403  0.56
2014 Chakraborty S, Ji H, Kabadi AM, Gersbach CA, Christoforou N, Leong KW. A CRISPR/Cas9-based system for reprogramming cell lineage specification. Stem Cell Reports. 3: 940-7. PMID 25448066 DOI: 10.1016/j.stemcr.2014.09.013  0.56
2014 Kabadi AM, Gersbach CA. Special issue on engineered DNA-binding proteins. Acs Synthetic Biology. 3: 702-3. PMID 25324185 DOI: 10.1021/sb500325e  0.56
2014 Gersbach CA. Genome engineering: the next genomic revolution. Nature Methods. 11: 1009-11. PMID 25264777 DOI: 10.1038/nmeth.3113  0.56
2014 Kabadi AM, Ousterout DG, Hilton IB, Gersbach CA. Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Research. 42: e147. PMID 25122746 DOI: 10.1093/nar/gku749  0.56
2014 Kabadi AM, Gersbach CA. Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression. Methods (San Diego, Calif.). 69: 188-97. PMID 25010559 DOI: 10.1016/j.ymeth.2014.06.014  0.56
2014 Gersbach CA, Perez-Pinera P. Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine. Expert Opinion On Therapeutic Targets. 18: 835-9. PMID 24917359 DOI: 10.1517/14728222.2014.913572  0.56
2014 Gersbach CA, Gaj T, Barbas CF. Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies. Accounts of Chemical Research. 47: 2309-18. PMID 24877793 DOI: 10.1021/ar500039w  0.56
2014 High K, Gregory PD, Gersbach C. CRISPR technology for gene therapy Nature Medicine. 20: 476-477. PMID 24804755  0.56
2014 Glass KA, Link JM, Brunger JM, Moutos FT, Gersbach CA, Guilak F. Tissue-engineered cartilage with inducible and tunable immunomodulatory properties. Biomaterials. 35: 5921-31. PMID 24767790 DOI: 10.1016/j.biomaterials.2014.03.073  0.56
2014 Polstein LR, Gersbach CA. Light-inducible gene regulation with engineered zinc finger proteins. Methods in Molecular Biology (Clifton, N.J.). 1148: 89-107. PMID 24718797 DOI: 10.1007/978-1-4939-0470-9_7  0.56
2014 Brunger JM, Huynh NP, Guenther CM, Perez-Pinera P, Moutos FT, Sanchez-Adams J, Gersbach CA, Guilak F. Scaffold-mediated lentiviral transduction for functional tissue engineering of cartilage. Proceedings of the National Academy of Sciences of the United States of America. 111: E798-806. PMID 24550481 DOI: 10.1073/pnas.1321744111  0.56
2014 Gersbach CA, Gaj T, Barbas CF. Comparing genome editing technologies Genetic Engineering and Biotechnology News. 34: 1+32-34. DOI: 10.1089/gen.34.05.02  0.56
2014 Thakore PI, Gersbach CA. Genome Engineering for Therapeutic Applications Translating Gene Therapy to the Clinic: Techniques and Approaches. 27-43. DOI: 10.1016/B978-0-12-800563-7.00003-8  0.56
2013 Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nature Methods. 10: 973-6. PMID 23892895 DOI: 10.1038/nmeth.2600  0.56
2013 Ousterout DG, Perez-Pinera P, Thakore PI, Kabadi AM, Brown MT, Qin X, Fedrigo O, Mouly V, Tremblay JP, Gersbach CA. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1718-26. PMID 23732986 DOI: 10.1038/mt.2013.111  0.56
2013 Dumbauld DW, Lee TT, Singh A, Scrimgeour J, Gersbach CA, Zamir EA, Fu J, Chen CS, Curtis JE, Craig SW, García AJ. How vinculin regulates force transmission. Proceedings of the National Academy of Sciences of the United States of America. 110: 9788-93. PMID 23716647 DOI: 10.1073/pnas.1216209110  0.56
2013 Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in Biotechnology. 31: 397-405. PMID 23664777 DOI: 10.1016/j.tibtech.2013.04.004  0.56
2013 Gibson TM, Gersbach CA. The role of single-cell analyses in understanding cell lineage commitment. Biotechnology Journal. 8: 397-407. PMID 23520130 DOI: 10.1002/biot.201200201  0.56
2013 Perez-Pinera P, Ousterout DG, Brunger JM, Farin AM, Glass KA, Guilak F, Crawford GE, Hartemink AJ, Gersbach CA. Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nature Methods. 10: 239-42. PMID 23377379 DOI: 10.1038/nmeth.2361  0.56
2013 Bhakta MS, Henry IM, Ousterout DG, Das KT, Lockwood SH, Meckler JF, Wallen MC, Zykovich A, Yu Y, Leo H, Xu L, Gersbach CA, Segal DJ. Highly active zinc-finger nucleases by extended modular assembly. Genome Research. 23: 530-8. PMID 23222846 DOI: 10.1101/gr.143693.112  0.56
2013 Duvall CL, Prokop A, Gersbach CA, Davidson JM. Gene Delivery into Cells and Tissues Principles of Tissue Engineering: Fourth Edition. 687-723. DOI: 10.1016/B978-0-12-398358-9.00035-5  0.56
2013 Gersbach CA. Engineered Proteins for Controlling Gene Expression Handbook of Stem Cells. 1: 125-138. DOI: 10.1016/B978-0-12-385942-6.00013-5  0.56
2013 Gersbach CA, Barbas CF. Targeted plasmid integration into the Human Genome by engineered recombinases Topics in Current Genetics. 23: 267-284. DOI: 10.1007/978-94-007-4531-5_10  0.56
2012 Polstein LR, Gersbach CA. Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors. Journal of the American Chemical Society. 134: 16480-3. PMID 22963237 DOI: 10.1021/ja3065667  0.56
2012 Perez-Pinera P, Ousterout DG, Gersbach CA. Advances in targeted genome editing. Current Opinion in Chemical Biology. 16: 268-77. PMID 22819644 DOI: 10.1016/j.cbpa.2012.06.007  0.56
2012 Perez-Pinera P, Ousterout DG, Brown MT, Gersbach CA. Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases. Nucleic Acids Research. 40: 3741-52. PMID 22169954 DOI: 10.1093/nar/gkr1214  0.56
2012 Polstein LR, Gersbach CA. Photoregulated gene expression in human cells with light-inducible engineered transcription factors Asme 2012 Summer Bioengineering Conference, Sbc 2012. 351-352. DOI: 10.1115/SBC2012-80573  0.56
2011 Gersbach CA, Gaj T, Gordley RM, Mercer AC, Barbas CF. Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase. Nucleic Acids Research. 39: 7868-78. PMID 21653554 DOI: 10.1093/nar/gkr421  0.56
2011 Gaj T, Mercer AC, Gersbach CA, Gordley RM, Barbas CF. Structure-guided reprogramming of serine recombinase DNA sequence specificity. Proceedings of the National Academy of Sciences of the United States of America. 108: 498-503. PMID 21187418 DOI: 10.1073/pnas.1014214108  0.56
2011 Chung HS, Raetz CR. Dioxygenases in Burkholderia ambifaria and Yersinia pestis that hydroxylate the outer Kdo unit of lipopolysaccharide. Proceedings of the National Academy of Sciences of the United States of America. 108: 510-5. PMID 21178073 DOI: 10.1073/pnas.1016462108  0.56
2011 Gersbach CA. Engineered bioactive molecules Comprehensive Biomaterials. 5: 131-145.  0.56
2010 Gersbach CA, Gaj T, Gordley RM, Barbas CF. Directed evolution of recombinase specificity by split gene reassembly. Nucleic Acids Research. 38: 4198-206. PMID 20194120 DOI: 10.1093/nar/gkq125  0.56
2009 Gordley RM, Gersbach CA, Barbas CF. Synthesis of programmable integrases. Proceedings of the National Academy of Sciences of the United States of America. 106: 5053-8. PMID 19282480 DOI: 10.1073/pnas.0812502106  0.56
2007 Gersbach CA, Coyer SR, Le Doux JM, García AJ. Biomaterial-mediated retroviral gene transfer using self-assembled monolayers. Biomaterials. 28: 5121-7. PMID 17698189 DOI: 10.1016/j.biomaterials.2007.07.047  0.56
2007 Pregizer S, Barski A, Gersbach CA, García AJ, Frenkel B. Identification of novel Runx2 targets in osteoblasts: cell type-specific BMP-dependent regulation of Tram2. Journal of Cellular Biochemistry. 102: 1458-71. PMID 17486635 DOI: 10.1002/jcb.21366  0.56
2007 Gersbach CA, Phillips JE, García AJ. Genetic engineering for skeletal regenerative medicine. Annual Review of Biomedical Engineering. 9: 87-119. PMID 17425467 DOI: 10.1146/annurev.bioeng.9.060906.151949  0.56
2007 Gersbach CA, Guldberg RE, García AJ. In vitro and in vivo osteoblastic differentiation of BMP-2- and Runx2-engineered skeletal myoblasts. Journal of Cellular Biochemistry. 100: 1324-36. PMID 17131362 DOI: 10.1002/jcb.21118  0.56
2007 Phillips JE, Gersbach CA, García AJ. Virus-based gene therapy strategies for bone regeneration. Biomaterials. 28: 211-29. PMID 16928397 DOI: 10.1016/j.biomaterials.2006.07.032  0.56
2006 Gersbach CA, Le Doux JM, Guldberg RE, García AJ. Inducible regulation of Runx2-stimulated osteogenesis. Gene Therapy. 13: 873-82. PMID 16496016 DOI: 10.1038/  0.56
2006 Phillips JE, Gersbach CA, Wojtowicz AM, García AJ. Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation. Journal of Cell Science. 119: 581-91. PMID 16443755 DOI: 10.1242/jcs.02758  0.56
2005 Lan MA, Gersbach CA, Michael KE, Keselowsky BG, García AJ. Myoblast proliferation and differentiation on fibronectin-coated self assembled monolayers presenting different surface chemistries. Biomaterials. 26: 4523-31. PMID 15722121 DOI: 10.1016/j.biomaterials.2004.11.028  0.56
2005 Gersbach CA, Phillips JE, Guldberg RE, García AJ. Runx2-genetically engineered cells for bone tissue engineering Proceedings of the 2005 Summer Bioengineering Conference. 2005: 603-604.  0.56
2004 Gersbach CA, Byers BA, Pavlath GK, Guldberg RE, García AJ. Runx2/Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro. Biotechnology and Bioengineering. 88: 369-78. PMID 15486943 DOI: 10.1002/bit.20251  0.56
2004 Gersbach CA, Byers BA, Pavlath GK, García AJ. Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype. Experimental Cell Research. 300: 406-17. PMID 15475005 DOI: 10.1016/j.yexcr.2004.07.031  0.56
2004 Gersbach CA, Byers BA, Guldberg RE, Pavlath GK, Garcia AJ. Runx2-stimulated transdifferentiation of primary skeletal myoblasts into an osteoblastic mineralizing phenotype for bone tissue engineering Transactions - 7th World Biomaterials Congress. 328.  0.56
2003 García AJ, Guldberg RE, Byers BA, Gersbach CA, Phillips JE. Addressing cell-sourcing limitations with gene therapy. Ieee Engineering in Medicine and Biology Magazine : the Quarterly Magazine of the Engineering in Medicine & Biology Society. 22: 65-70. PMID 14699938 DOI: 10.1109/MEMB.2003.1256274  0.56
Show low-probability matches.